NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 IND-SWIFT LABORATORIES LIMITED – ANNUAL REPORT FY2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from Operations: ₹63,588.85 La | 2026-09-05 |
| Q1 FY27 earnings call IND-SWIFT LABORATORIES LTD. - Q1 FY27 SUMMARY HEADLINE NUMBERS • Operating income grew 21.16% year-on-year to ₹186.08 crore in Q1 FY27, from ₹153.58 | 2026-08-20 |
| Investor presentation · Q1 FY27 IND-SWIFT LABORATORIES LTD – INVESTOR SUMMARY Q1 FY27 UN-AUDITED FINANCIAL RESULTS (Quarter Ended June 30, 2026) --- HEADLINE NUMBERS • Q1 FY27 Tot | 2026-08-17 |
| Quarterly results · Q1 FY27 IND-SWIFT LABORATORIES LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Standalone Net Profit (Q1): ₹24.44 Crores (vs ₹8.12 Crores in Q1 FY2025-26) | 2026-08-10 |
| Quarterly results · Q4 FY26 IND-SWIFT LABORATORIES LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • FY 2025-26 Net Profit (Standalone): Rs. 255.68 Lakhs (aft | 2026-05-28 |
| Investor presentation INVESTOR SUMMARY: IND-SWIFT LABORATORIES LTD Q3 FY26 Un-Audited Financial Results (Quarter Ended December 31, 2025) --- HEADLINE NUMBERS • Q3 FY26 | 2026-02-04 |
| Quarterly results · Q2 FY26 IND-SWIFT LABORATORIES LIMITED – FINANCIAL SUMMARY Document: Board Meeting & Q2 FY2025-26 Results (14 November 2025) --- HEADLINE NUMBERS • Standal | 2025-11-14 |
| Annual report FY2025 IND-SWIFT LABORATORIES LTD – ANNUAL REPORT FY2024-25 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹56,171 crore (FY2025) vs ₹170,915 crore (F | 2025-09-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Jammu facility upgrade to EUGMP and PICS compliance targets 100 crores revenue Ind-Swift Laboratories Limited announced plans to upgrade its Jammu manufacturing facility to EU-GMP and PICS standards, enabling it to serve European and other highly regulated internationa | 2026-08-18 |
| MOU execution for warehouse facility development Execution of MOU for development of the Warehouse Facility of the Company | 2026-07-28 |
| Upgrade Samba facility with ₹400M investment for EU-GMP compliance Ind-Swift Laboratories announced a ₹400 million investment to upgrade its Samba facility to achieve EU-GMP (European Good Manufacturing Practice) and PIC/S compliance standards. These are cr | 2026-02-16 |
| Trading approval obtained for equity shares issued under approved amalgamation scheme The company has obtained trading approval from stock exchanges for 81,24,698 new equity shares worth Rs. 10 each. These shares were issued as part of an approved Scheme of Amalgamation (merg | 2025-12-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ind-Swift Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.